Once-weekly dosing of recombinant human erthyropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing

Annals of Oncology

Volumn 15, Issue 11, 2004, Pages 1684-1690

  Stasi, Roberto ^a   Brunetti, M ^a   Terzoli, E ^b   Abruzzese, E ^c   Amadori, S ^c  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b Istituti Fisioterapici Ospitalieri Rome   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apoptosis; Erythropoietin; Myelodysplastic syndrome; Schedule

Indexed keywords

CD34 ANTIGEN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; BURST FORMING UNIT E; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ERYTHEMA; ERYTHROID CELL; ERYTHROPOIESIS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFECTION; MALE; MYELODYSPLASTIC SYNDROME; PAIN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME;

EID: 9444251808     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh428     Document Type: Article

References (24)

1. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71.
2. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-2320.
3. Alessandrino EP, Amadori S, Barosi G et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87: 1286-1306.
4. Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200.
5. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57: 411-418.
6. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
7. Cazzola M, Beguin Y, Kloczko J et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122: 386-393.
8. Musto P, Falcone A, Sanpaolo G et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 2003; 122: 269-271.
9. Aloe-Spiriti MA. Effects of 40.000 IU bi-weekly induction dose of Epoetin alpha followed by 40.000 IU once weekly in low risk myelodysplastic syndrome patients. Blood 2002; 100: 790a.
10. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
13. Stasi R, Brunetti M, Bussa S et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997; 3: 733-739.
14. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78: 1658-1663.
15. Goy A, Belanger C, Casadevall N et al. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 1993; 84: 232-237.
16. Bowen D, Ehmer B, Neubert P et al. The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol 1991; 19: 613-616.
17. Aloe Spiriti MA, Petti MC, Latagliata R et al. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report. Haematologica 1993; 78: 123-126.
18. Stone RM, Bernstein SH, Demetri G et al. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res 1994; 18: 769-776.
19. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998; 103: 1070-1074.
20. Terpos E, Mougiou A, Kouraklis A et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002; 118: 174-180.
21. Merchav S, Nielsen OJ, Rosenbaum H et al. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukemia 1990; 4: 771-774.
22. Parker JE, Mufti GJ, Rasool F et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
23. Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99: 1578-1584.
24. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998; 22: 1123-1136.